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Functional characterization of biodegradable
nanoparticles as antigen delivery system
A. Petrizzo1†, C. Conte2†, M. Tagliamonte1, M. Napolitano3, K. Bifulco4, V. Carriero4, A. De Stradis5, M. L. Tornesello1,
F. M. Buonaguro1, F. Quaglia2 and L. Buonaguro1*
Background: Peptide based vaccines may suffer from limited stability and inefficient delivery to professional antigen-
presenting cells (APCs), such as dendritic cells (DCs). In order to overcome such limitations, several types of biodegradable
nanoparticles (NPs) have been developed as carrier system for antigens. The present study describes for the first time the
extensive biological characterization of cationic NPs made of poly (D,L-lactide-co-glycolide) (PLGA) and polyethylenimine
(PLGA/PEI) as delivery system for protein/peptide antigens, with potential in therapeutic cancer vaccine development.
Results: Flow cytometry as well as confocal laser scanning microscopy (CLSM) showed that PLGA/PEI NPs are more
readily taken up than PLGA NPs by both human CD14+ monocytes and mouse Hepa 1–6 hepatoma cell line. No signs
of toxicity were observed in either cellular setting. Sequential image acquisition by TEM showed an intracellular apical
localization for PLGA NPs and a perinuclear localization for PLGA/PEI NPs. Both NPs showed a clathrin-dependent as well
as a caveolin-dependent internalization pathway and, once in the cells, they formed multivesicular endosomes (MVE).
Finally, an ex vivo priming experiment showed that PLGA/PEI NPs are comparable to PLGA NPs in delivering a non-self
antigen (i.e., ovalbumin - OVA) to immature dendritic cells (imDCs), which matured and induced autologous naïve CD4+
T cells to differentiate to memory (i.e., central memory and effector memory) cells. Such a differentiation was associated
with a Th1 phenotype suggesting a downstream activation and amplification of a CD8+ T cell cytotoxic response. The
same OVA antigen in a soluble form was unable to induce maturation of DCs, indicating that both NP formulations
provided an intrinsic adjuvanting effect combined to efficient antigen delivery.
Conclusions: Our study represents the first report on side-by-side comparison of PLGA and PLGA/PEI NPs as strategy for
protein antigen delivery. PLGA/PEI NPs are superior for cellular uptake and antigen delivery as compared to PLGA NPs.
Such an evidence suggests their great potential value for vaccine development, including therapeutic cancer vaccines.
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Background
Our improved understanding of antigen recognition and
presentation by professional APCs to effector lympho-
cytes has led to the development of several cancer vac-
cine concepts, most of which based on peptides [1].
Cancer vaccines based on autologous DCs loaded ex
vivo with peptides have been developed and tested in sev-
eral clinical trials with controversial results (reviewed in
[2, 3]) due to several reasons, including the variable effi-
ciency of the generated DCs in antigen presentation [4].
Recently, biocompatible PLGA NPs have generated
tremendous interest in antigen delivery due to several
features, including 1) antigen protection from early deg-
radation in biological environments [5]; 2) prolonged
antigen presentation by DCs for induction of B and T
cell response after both systemic and mucosal adminis-
tration [6]; 3) antigen reservoir for stimulation of CTL
response [7]. However plain PLGA NPs have suboptimal
adjuvant properties in vivo resulting in poor DC matur-
ation [8].
Several strategies have been developed so far to en-
hance NP uptake by DCs, including surface decoration
with ligands of DC receptors as well as modification of
surface charge with polycations able to promote electro-
static interactions with anionic cell membranes [9]. The
latter approach was found to be successful when PLGA
* Correspondence: l.buonaguro@istitutotumori.na.it
†Equal contributors
1Laboratoy Molecular Biology and Viral Oncology, Department of
Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori
“Fondazione Pascale” - IRCCS, Via Mariano Semmola 142, 80131 Naples, Italy
Full list of author information is available at the end of the article
© 2015 Petrizzo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Petrizzo et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:114 
DOI 10.1186/s13046-015-0231-9
NPs were modified with protamine that enhanced the
NP properties of inducing activation and maturation of
bone-marrow DCs [10, 11].
In this perspective, polycations may represent a prom-
ising option in “nanovaccine” approaches to modify sur-
face properties of PLGA NPs. Indeed, polyethylenimine
(PEI) has been recently shown to have anticancer/immu-
nostimulatory activities [12] as well as adjuvant proper-
ties for glycoprotein antigens administered at mucosal
sites [13].
On these premises, in the present study we developed
NPs made of PLGA, alone or in association with PEI, to
assess whether the modification would result in en-
hancement of both NP cellular uptake and presentation
of the carried non-self OVA antigen [14].
The rate of uptake and intracellular distribution of
both NPs was assessed in a murine Hepa 1–6 hepatoma
cell line and in human PBMCs.
Finally, an ex vivo priming experiment showed that
both NPs were efficient in delivering the OVA antigen to
immature dendritic cells (imDCs), inducing their matur-
ation. Such matured DCs (mDCs) were able to prime
autologous naïve CD4+ T cells to differentiate into mem-
ory T cells with a Th1 phenotype. This is suggestive of a
downstream activation and amplification of a CD8+ T
cell cytotoxic response, which is the relevant one in a
therapeutic cancer vaccine setting.
Results
Nanoparticle properties
Properties of the produced NPs are reported in Table 1.
The size of NPs was increased by OVA entrapment only
in the case of PLGA NPs. Negative zeta potential of
PLGA NPs switched to positive values in the case of
PLGA/PEI NPs, suggesting that PEI was partly present
onto NP surface. Lower entrapment efficiency of OVA
was found for OVA-PLGA/PEI NPs, presumably due to
the occurrence of electrostatic interactions between
OVA and PEI, resulting in both localization of an OVA
fraction onto NP surface and escape from the polymer
matrix to the external phase during particle formation.
TEM analysis of NP morphology showed monolayer
spheroid particles with a diameter ranging from 100 to
200 nm for PLGA NPs (Fig. 1a and c) and 50 to 250 nm
for PLGA/PEI NPs (Fig. 1b and d) in line with values ob-
served by PCS.
NP stability in both DMEM and RPMI culture media
was analyzed. Both unloaded and OVA-PLGA NPs
showed a satisfactory stability in the media. Conversely,
the presence of PEI induced a remarkable aggregation of
the NPs, likely due to interactions with serum proteins
(Fig. 2a and b).
NP uptake in human PBMCs and mouse Hepa 1–6 cell line
Cellular uptake studies were performed in a murine
Hepa 1–6 hepatoma cell line and in human PBMCs.
Fluorescently-labeled NPs prepared from a Rhodamine-
PLGA conjugate (Additional file 1: Table S1) were
employed for cellular uptake studies.
The percentage of cellular uptake was evaluated at se-
quential time points, loading both cell types with increas-
ing doses of both NPs (20, 50 and 100 μg/mL) (Fig. 3).
Uptake of PLGA-Rhod NPs showed a dose- and time-
dependent curve, reaching the saturation with the highest
dose (i.e., 100 μg/mL) in Hepa 1–6 cells, and with all three
doses in PBMCs, after 4–24 h (Fig. 3a and b). On the con-
trary, cellular uptake of PLGA-Rhod/PEI NPs in both cell
types showed a dose- and time-independent curve, reach-
ing the saturation as soon as 15 min, regardless the
amount of NPs used for induction (Fig. 3c and d).
Moreover, the pattern of intracellular fluorescence
showed a dose response curve in both cell types with
both NPs (Fig. 3e-h). Considering the Hepa 1–6, for
each of the three doses, the cellular fluorescence in-
duced by PLGA-Rhod NP uptake was characterized
by an initial lag phase, with a spike at 4 h, followed
by a steep decline at 24 h (Fig. 3e), while the fluores-
cence induced by PLGA-Rhod/PEI NP uptake peaked
as soon as at 15 min, with a MFI (mean fluorescence
intensity) >20 fold than with PLGA-Rhod NPs, to
sharply reduce at subsequent time points, with a
small rebound at 4 h. This finding was consistently
observed for all three doses (Fig. 3g).
CD14+ monocytes showed a different profile (Fig. 3f
and h). Indeed, the cellular fluorescence induced by up-
take of PLGA-Rhod NPs progressively increased at dif-
ferent time points with the lowest dose (20 μg/mL),
while it progressively decreased for the first hour and









OVA actual loading mg/100 mg NPs (Entrapment
efficiency %)a
PLGA NPs - 175 ± 12 0.165 −32.8 ± 5.6 - -
OVA-PLGA NPs 4 253 ± 16 0.166 −32.1 ± 2.0 - 3.6 ± 0.7 (92.9 ± 17.4)
PLGA/PEI NPs - 172 ± 5 0.162 +36.3 ± 4.0 6.2 -
OVA-PLGA/PEI
NPs
4 161 ± 9 0.147 +42.9 ± 5.3 6.6 3.3 ± 0.4 (77.5 ± 10.3)
aRatio between actual and theoretical loading x 100
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sharply increased at 4 and 24 h with the higher doses
(Fig. 3f). Moreover, unlike Hepa 1–6 cell line, the cellular
fluorescence induced by uptake of PLGA-Rhod/PEI NPs
in CD14+ monocytes was characterized by a “parabola-
like” pattern similar to the one observed for PLGA-Rhod
NPs, with a sharp increase at 24 h reaching >3 fold MFI
values (Fig. 3h).
Analysis of intracellular NP distribution by CLSM
Intracellular nanoparticle distribution was evaluated at dif-
ferent time points by fluorescence microscopy and CLSM
in Hepa 1–6 cells and PBMCs loaded with 50 μg/mL of
PLGA and PLGA-Rhod/PEI NPs.
The fluorescence microscopy analysis showed that
PLGA-Rhod NPs exhibited a low aggregation profile and
a time-dependent internalization in both cell types as in-
dicated by the appearance, already after 30 min, of punc-
tuate red fluorescent spots that progressively pervaded
the entire cytoplasm (Fig. 4a and b). Conversely, an in-
crease in size of NPs due to their aggregation was ob-
served in both cell types loaded with PLGA-Rhod/PEI
NPs. A massive internalization of clustered PLGA-Rhod/
PEI NPs was observed already after 1 h incubation, in
both Hepa 1–6 and PBMCs (Fig. 4c and d). Such obser-
vations are fully in agreement with data on hydro-
dynamic diameter (Fig. 2a and b).
The time dependent internalization of PLGA-Rhod
NPs by monocytes exposed to 50 μg/mL PLGA-Rhod
NPs for 30 min, 1 h, 4 h and 24 h was further confirmed
Fig. 1 TEM morphology study. TEM analysis of PLGA (a and c) and PLGA/PEI (b and d) NPs
Fig. 2 NP stability in cell culture media. Stability of NPs was
analyzed at 37 °C in DMEM (a) and RPMI 1640 (b), respectively,
by monitoring size by PCS. Data are reported as mean of three
independent experiments ± SD
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by z-stack analysis of confocal images taken through the
cell at 0.1 μm intervals (Fig. 5a-d). Internalization of
PLGA-Rhod NPs occurred already after 30 min (Fig. 5 a)
and increased after 1 h (Fig. 5b) and 4 h (Fig. 5c). After
24 h, cells showed a diffuse intra-cytoplasmic fluores-
cence together with smaller fluorescent spots, suggesting
that, at this time point, escape from endolysosomes of
PLGA-Rhod NPs might occur (Fig. 5d). The analysis of
cells loaded with PLGA-Rhod/PEI NPs was not possible
because of extensive cellular aggregation.
Analysis of NP intracellular compartmentalization by TEM
TEM analysis of PBMCs showed a significantly different
pattern of intracellular localization according to the NP
formulation loaded. PLGA NPs were internalized as sin-
gle particles and localized mostly at the cellular apical
area for the entire incubation period (Fig. 6a-c). On the
contrary, PLGA/PEI NPs were internalized as multiple
particles, confirming particle-to-particle interactions
found in the presence of proteins and more extensive
uptake observed by flow cytometry as well as CLSM.
Moreover, PLGA/PEI NPs were massively internalized
already at 15 min post treatment (Fig. 6d), moved to-
wards cellular core areas at 30 min (Fig. 6e) and reached
the perinuclear region at 24 h (Fig. 6f ). Both NPs
showed a clathrin-dependent (Fig. 6g and i) and a
caveolin-dependent (Fig. 6j and k) internalization path-
way [15] and, once in the cells, they formed multivesicu-
lar endosomes (MVE) (Fig. 6h) [16]. Moreover, PBMCs
loaded with PLGA PEI NPs often showed interactions
between vesicles and nuclear membrane (Fig. 6l).
Effect of NPs on ex vivo activation of naïve CD4+ T cells
MDDCs obtained from human PBMCs by standard pro-
cedure [17] were pulsed with 1.55 and 7.75 μg OVA (1X
and 5X dose), either soluble or encapsulated in NPs.
Loaded cells did not show any significant toxicity due to
NP loading, as assessed by MTT assay (data not shown).
Half of the immature DCs pulsed with the two doses
of OVA (OVA-imDCs) were further matured by a 48 h
treatment with LPS (200 ng/mL), resulting in mature
DCs (OVA-mDCs). Both OVA-imDCs and OVA-mDCs
were used to prime autologous naïve CD4+ T cells la-
beled with CFSE in a 1:5 ratio.
After 7 days of co-cultivation with imDCs or mDCs
pulsed with the different OVA formulations, the absolute
number of CD4+ T cells was assessed(Fig. 7a and b). As
expected, the number of CD4+ T cells was significantly
higher when co-cultured with mDCs and no significant
difference was found among the different antigen formu-
lations. The only major difference was observed in the
co-culture with mDCs pulsed with 5X dose of OVA-
PLGA/PEI NPs, in which the absolute number of CD4+
T cells was unexpectedly almost 2 logs lower than the
others (5.6x103) (Fig. 7b). The co-cultivation with
imDCs showed that the OVA antigen was able to induce
a significant increase in the number of CD4+ T cells only
when formulated in NPs. No significant difference was
observed between the two NP formulations. (Fig. 7a).
In addition, the percentage of proliferating cells was
evaluated as further parameter (Table 2). Immature DCs
induced proliferation of 31.9 and 24.8 % of CD4+ T cells
when loaded with OVA-PLGA NPs at 1X and 5X dose,
Fig. 3 NP uptake in human PBMCs and mouse Hepa 1–6 cell line. Percent of Hepa 1–6 (a and c) and monocytes (b and d) which uptake PLGA-Rhod NPs
(a and b) and PLGA-Rhod/PEI NPs (c and d) at different time points. Mean fluorescence intensity (MFI) of Hepa 1–6 (e and g) and monocytes
(f and h) loaded with different concentration of PLGA-Rhod NPs (e and f) and PLGA-Rhod/PEI NPs (g and h), at different time points
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respectively. This was approx. a 2 fold increase com-
pared to the proliferation induced by imDCs pulsed with
the same doses of soluble OVA (17.4 and 12.8 %, re-
spectively). Such an increase in proliferation was not ob-
served in CD4+ T cells co-cultivated with imDCs loaded
with either doses of OVA-PLGA/PEI NPs (17.1 and
5.0 %, respectively). Indeed, the 5X dose of OVA-PLGA/
PEI NPs seemed to have an inhibitory effect on the over-
all CD4+ T cell proliferation.
On the contrary, mDCs induced similar levels of pro-
liferating CD4+ T cells when loaded with either OVA-
PLGA NPs or soluble OVA at both 1X and 5X doses,
without any significant increment given by the antigen
encapsulation in NPs (above 30 %). Also for mDCs,
PLGA/PEI OVA NPs seemed to have an inhibitory effect
on the overall CD4+ T cell proliferation at both doses
(approx. 16.0 %).
Naïve unstimulated CD4+ T cells showed 0.1 % basal
activation, whereas CD4+ T cells pulsed with PHA
showed a 27.4 % proliferation.
Effect of NPs on ex vivo differentiation of naïve CD4+ T cells
Proliferating CD4+ T cells induced by co-cultivation with
imDCs as well as mDCs were fully characterized for
their differentiation pattern. As expected, OVA antigen
presentation by imDCs to CD4+ T cells induced a pro-
gressive reduction of CD45RA+/CD45RO−/CD62L+
naïve T cells, with a complementary increase of the
effector memory and central memory T cells (Fig. 7c).
Such an effect was more evident when OVA antigen was
delivered to imDCs in both NP formulations. Similarly,
OVA antigen presentation by mDCs to CD4+ T cells
induced a progressive reduction of CD45RA+/CD45RO
−/CD62L+ naïve T cells with a complementary increase
of the effector memory and central memory T cells
(Fig. 7d). However, such an effect was very comparable
regardless the way of OVA antigen delivery to DCs (i.e.,
soluble or in NP formulation). Overall, OVA presenta-
tion by imDCs and mDCs was equally effective in indu-
cing effector T cells. In particular, effector memory T
cells were more efficiently induced by imDCs, whereas
Fig. 4 Intracellular NP distribution evaluated by fluorescence microscopy. Hepa 1–6 (a and c) and monocytes (b and d) were loaded with either
50 μg/mL PLGA-Rhod NPs (a and b) or PLGA-Rhod/PEI NPs (c and d) at different time points. Original magnification: 400X
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central memory T cells were more efficiently induced by
mDCs.
Effect of NPs on cytokine secretion
IFN-γ and IL-10 production was evaluated in cell super-
natants at the end of the 7 days co-culture. In particular,
CD4+ T cells co-cultured with imDCs loaded with soluble
OVA did not produce any detectable cytokine level unless
OVA was delivered at a 500X dose (Fig. 8a and b). On the
contrary, imDCs loaded with NPs loaded with OVA were
extremely effective in inducing both IFN-γ and IL-10 pro-
duction by CD4+ T cells (IFN-γ > IL-10). In particular, ei-
ther doses of OVA-PLGA NPs induced 2–3 log increase
in cytokine production over the same doses of OVA as
soluble antigen. The 1X dose of OVA-PLGA/PEI NPs was
less effective but still induced an approx. 100 fold increase
in cytokine production compared to the same dose of sol-
uble OVA. Interestingly, the 5X dose of OVA-PLGA/PEI
NPs did not increase IFN-γ production (Fig. 8a).
On the other hand, CD4+ T cells stimulated by mDCs
produced very high levels of both cytokines (IFN-γ > IL-10)
with a limited 2–4 fold increase provided by NPs vs. soluble
delivery of OVA antigen. Indeed, the highest production
was observed when mDCs were stimulated by either the
500X dose of soluble OVA or the 1X and 5X doses of
OVA-PLGA NPs. Interestingly, either doses of PLGA/PEI
OVA NPs did not induce an increase in cytokine produc-
tion compared to corresponding dose of soluble antigen
(Fig. 8a and b).
In addition, to determine which subset of CD4+ T cells
(i.e., naïve T cells, effector T cells, central memory, ef-
fector memory) was the major contributor to the ob-
served cytokine production, a correlation analysis was
performed between the percentage of distinct T cell phe-
notypes and the cytokine levels.
The correlation analysis was performed combining the
four subsets in two distinct groups: the CD45RA+ (naïve
and effector T cells) and the CD45RO+ (effector memory
and central memory T cells) cells (Fig. 8c and d). In this
setting, the analysis clearly showed a very strong direct
correlation between the pattern of CD45RO+ T cells and
cytokine production with almost superimposable curves
in the mDCs setting (correlation coeff. 0.62; p = 0.01)
(Fig. 8d). Similarly, the pattern of CD45RA+ cells and
Fig. 5 Analysis of intracellular NP distribution by CLSM. monocytes were loaded with 50 μg/mL PLGA NPs at different time points (a 30 min; b 1 h; c 4 h;
d 24 h). Z-series images represent focal planes corresponding to 0.1 μm vertical interval. Internalization areas are indicated by arrows. Original magnification:
630X. Scale bar: 10 μm and 5 μm
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cytokine production showed a very strong inverse correl-
ation (correlation coeff. –0.47 p = 0.01) (Fig. 8d).
Discussion
A functional characterization of biodegradable NPs
based on PLGA modified with PEI (PLGA/PEI) was per-
formed in the present study. Their property as carriers
to promote Ag presentation in human DCs was com-
pared to plain PLGA NPs. Unloaded and OVA-loaded
PLGA and PLGA/PEI NPs showed very similar size with
opposite zeta potential (Table 1). Both NPs entrapped
OVA with high encapsulation efficiency. However,
PLGA/PEI NPs exhibited a tendency to aggregation in
the presence of FBS-enriched cell culture media as pre-
viously found for PEI-coated PLGA NPs [18].
NP uptake was evaluated in mouse Hepa 1–6 continu-
ous cell line and in primary human PBMCs at different
concentrations and time points (Fig. 3). The uptake pro-
file of PLGA-Rhod/PEI NPs, analyzed by flow cytometry,
showed saturation soon after 15 min of incubation with
very high levels of fluorescent cells (Fig. 3c and d). On the
contrary, the uptake of PLGA-Rhod NPs by both cell types
showed a dose- and time-dependent increasing profile,
reaching the saturation level only after 24 h of incubation
(Fig. 3a and b). Such a result could be explained by the
positive surface charge of PLGA-Rhod/PEI NPs which facil-
itated adherence to negatively charged cellular membranes,
increasing intracellular uptake [19]. These results were fur-
ther confirmed by fluorescence microscopy as well as CLSM
analysis (Figs. 4 and 5). Indeed, PLGA-Rhod/PEI NPs
showed a marked trend to aggregation with a massive cellu-
lar internalization associated with a clear pattern of cellular
clustering. PLGA-Rhod NPs showed progressive internaliza-
tion in both cell types. A lack of correlation between the two
measurements was not surprising given that the number of
Rhodamine-labeled NPs entering each cell greatly varied.
TEM analysis confirmed a significantly different pat-
tern of intracellular localization according to the type of
Fig. 6 TEM ultrastructural study. Monocytes were loaded at different time points with either 50 μg/mL PLGA NPs (a 15 min; b 30 min; c 24 h) or
PLGA/PEI NPs (d 15 min; e 30 min; f 24 h). Clathrin-dependent (g and i) and caveolin-dependent (j and k) pathways; multivesicular enodosomes
(MVE) (h); interactions between vesicles and nuclear membrane (l) at 24 h post loading. NP internalization is indicated by asterisks. M: cytoplasmic
membrane, N: nucleus, R: endoplasmic reticulum, m: mitochondria
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NPs loaded on the cells. Indeed, while PLGA/PEI NPs
were taken up as multiple particles and reached the peri-
nuclear area (Fig. 6d - f ), PLGA NPs were taken up as
single particles and remained localized at the cellular ap-
ical area (Fig. 6a - c). Both NPs showed an internaliza-
tion pathway resembling clathrin-dependent (Fig. 6g and
i) as well as a caveolin-dependent (Fig. 6j and k) path-
ways [15]. Moreover, PBMCs loaded with PLGA/PEI
NPs often showed interactions between vesicles and nu-
clear membrane (Fig. 6l). The latter observation is ex-
tremely interesting because it has never been reported in
literature [20].
Finally, the efficacy of antigen delivery by PLGA and
PLGA/PEI NPs to antigen-presenting cells was assessed
in an ex vivo priming assay. Results showed that imDCs
loaded with 1X dose of OVA formulated in both NP for-
mulations induced the duplication of CD4+ T cells more
efficiently than soluble OVA (even at 500X dose)
(Fig. 7a). On the contrary, T cell duplication was induced
by mDCs at same levels when OVA was delivered to
Fig. 7 Effect of NPs on ex vivo differentiation of naïve CD4+ T cells. Absolute number of CD4+ T cells after 7 days of co-cultivation with either
OVA-imDCs (a) or OVA-mDCs (b). CD4+ T cell differentiation after 7 days of co-cultivation with either OVA-imDCs (c) or OVA-mDCs (d). Naïve
unstimulated CD4+ T cells represent basal activation. CD4+ T cells pulsed with PHA represent a positive proliferation control
Table 2 Percentage of proliferating CD4+ T cells co-cultivated
with imDCs or mDCs
Treatment Antigen presenting cells
imDCs mDCs
Null 1.7 % 0.1 %
OVA 17.4 % 32.0 %
OVA 5X 12.8 % 27.0 %
OVA 500X 22.4 % 28.9 %
OVA-PLGA 31.9 % 35.3 %
OVA-PLGA 5X 24.8 % 34.4 %
OVA-PLGA/PEI 17.1 % 16.0 %
OVA-PLGA/PEI 5X 5.0 % 15.9 %
PHA 26.2 % 27.4 %
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DCs as soluble antigen or encapsulated in both types of
NPs (Fig. 7b).
Such a result strongly indicates that the 1X dose of
OVA formulated in NPs is able to induce a maturation
of imDCs and subsequent activation of co-cultured au-
tologous naïve CD4+ T cells. On the contrary, OVA-
PLGA/PEI NPs, and in particular the 5X dose, seemed
to have an inhibitory effect on the overall CD4+ T cell
proliferation. This unexpected result is currently under
investigation.
Overall, the effect elicited was stronger when OVA
was encapsulated in mDCs than in imDCs, showing that
PLGA NPs are not able to induce a full maturation pat-
tern of DCs even in the presence of PEI. This strongly
supports the need for additional functionalization in
order to provide NPs with the full adjuvanting effect.
Differentiation of naïve CD4+ T cells varied according
to antigen delivery to imDCs and mDCs. Indeed, the
most evident increase in effector memory and central
memory T cells was observed when OVA antigen was
delivered to imDCs in NP formulations (Fig. 7c). On the
contrary, no striking difference in CD4+ T cell differenti-
ation was observed when OVA antigen was delivered to
mDCs either soluble or encapsulated in NPs (Fig. 7d). In
both experimental settings, the highest percentage of cen-
tral memory T cells was induced by the 1X dose of OVA-
PLGA NPs. The highest percentage of effector memory T
cells was induced by the 5X dose of OVA-PLGA NPs, in
the imDC setting, and by the 500X dose of soluble OVA in
the mDC setting. Conversely, in both experimental set-
tings, the highest percentage of effector T cells was induced
by the 5X dose of OVA-PLGA/PEI NPs. Such results pro-
vide evidence that either imDCs or mDCs when loaded
with 1X dose of OVA formulated in PLGA NPs are ex-
tremely effective in skewing naïve CD4+ T cells toward the
full spectrum of activated T cell phenotypes, including cen-
tral memory T cells which are crucial for the establishment
of immunological memory.
The apparent discordance between efficient uptake and
antigen presentation to T cells observed for PLGA/PEI
NPs, could be explained by the strong interaction occur-
ring between PEI and OVA. This could significantly reduce
the OVA protein release and its availability for processing
and presentation in the context of MHC II.
The evaluation of cytokines produced in the co-
cultures indicated a strong induction of a Th1
Fig. 8 Effect of NPs on cytokine secretion. IFN-γ (a) and IL-10 (b) production was evaluated after 7 days of T cell co-cultivation with either OVA-imDCs
or OVA-mDCs. A correlation analysis between CD4+ T cell subsets and cytokine production was performed in either OVA-imDCs (c) or OVA-mDCs
(d) co-culture setting
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phenotype, characterized by high levels of IFN-γ pro-
duction and lower levels of IL-10 (Fig. 8a and b). Such
CD4+ T helper phenotype is suggestive of an effective
CD8+ T cell response, as previously shown for PLGA
NPs [8, 21]. Only OVA encapsulated in NPs was able to
induce same levels of cytokines when presented to both
imDCs and mDCs. The modification with PEI did not
enhance the effect of PLGA NPs but even reduced it.
Additional studies are in progress to dissect such an ef-
fect. Soluble OVA induced the same effect in both DCs
only at the 500 X dose, at lower doses the effect was
observed in mDCs only.
The present results are in agreement with the evidence
that Th1 cells may produce both IFN-γ and its negative
regulator IL-10 as negative feed-back loop to contain an
excessive immune response [22, 23].
Furthermore, a correlation analysis showed that, in-
deed, the CD45RO+ memory T cells were the major if
not the only contributor to production of both cytokines
(Fig. 8 c and d), in agreement with previous studies [24],
suggesting the efficient induction by NPs of memory
CD4+ Th1 cells.
Conclusions
Biodegradable nanoparticles represent a very effective
antigen delivery system, providing sufficient co-
stimulatory signals able to induce innate as well as ef-
fector/memory adaptive immune responses with limited
antigen dose. The side-by-side comparison showed that
PLGA/PEI NPs, although providing higher cell uptake in
imDCs, are comparable to PLGA NPs in delivering the
OVA non-self antigen to DCs, inducing differentiation
of autologous naïve CD4+ T cells into memory cells with
a Th1 phenotype. In our experimental setting, modifica-
tion with PEI may represent a promising approach in
therapeutic cancer vaccine strategy development, but it
does not appear to enhance the antigen presentation ac-
tivity of PLGA NPs. Indeed, further optimization of the
model is required to parallel effects obtained with NPs
decorated with ligands of DC receptors.
Methods
Materials
Poly (D,L-lactide-co-glycolide) (PLGA) (50:50 Resomer
RG 502H inherent viscosity 0.16–0.24 dL/g) was pur-
chased from Boehringer Ingelheim (Ingelheim, Germany).
Polyethyleneimine (PEI, MW= 10–25 kDa branched),
poloxamer 188 (Pluronic® F68), Bradford reagent, potas-
sium phosphate dibasic and potassium phosphate mono-
basic, sodium azide, sodium chloride, copper (II) sulphate
and albumin from chicken egg white (OVA), were pur-
chased from Sigma-Aldrich. Sodium hydroxide was pro-
vided from Delchimica Scientific Glassware. Ethanol
(96 %), phosphoric acid (85 %), acetic acid, acetonitrile
and tetrahydrofuran were purchased from Carlo Erba
Reagenti (Milan, Italy).
Preparation of NPs
Unloaded and OVA-loaded PLGA and PLGA/PEI NPs
were prepared by a modified emulsion-solvent diffusion
technique [25]. An aqueous solution containing 1 mg of
OVA (50 μL) was emulsified by an ultrasound probe for 2
min at 3W (Sonicator 3000, Misonix, USA) with 1.5 mL
of PLGA (1.5 % w/v) and poloxamer 188 (1.5 % w/v) dis-
solved in methylene chloride. The resulting emulsion was
quickly added to 7.5 mL of ethanol, leading to an immedi-
ate precipitation of the polymer in the form of NPs. The
dispersion was diluted with 7.5 mL of ultrapure water and
stirred at RT for 1 h. The organic solvents were evapo-
rated under vacuum at 30 °C. NPs were washed twice with
ultrapure water under centrifugation at 13220 x g for 15
min. The pellet was re-dispersed in water and freeze-dried
for 24 h (addition of threalose 4:1 mass ratio to polymer
weight). Recovery yield of production process was evalu-
ated on an aliquot of NP dispersion by weighting the solid
residue after freeze-drying. Results are expressed as the ra-
tio of the actual NPs weight to the theoretical polymer
weight x 100. Fluorescent NPs were prepared analogously
by incorporating a 20 % w/w of PLGA-Rhod to PLGA NP
core [26].
Characterization of NPs
The hydrodynamic diameter (DH) and polydispersity index
(PI) of NPs were determined by Photon Correlation Spec-
troscopy (PCS) using a N5 Submicron Particle Size
Analyzer (Beckman-Coulter). A NP dispersion was diluted
in Milli-Q water at intensity in the range 104–106 counts/s
and measurements were performed at 25 °C on 90° angle.
Results are reported as mean DH of three separate mea-
surements on three different batches ± SD. Size of NPs
stored in the dark at 4 °C for 3 months was monitored too.
Zeta potential was determined by analyzing a NP dis-
persion in water on a Zetasizer Nano Z (Malvern
Instruments Ltd.). Results are reported as mean of
three separate measurements of three different batches
(n = 9) ± SD.
PEI amount associated to NPs
PEI was quantified by a colorimetric method developed
by us. To this purpose, 0.5 mg of freeze-dried PLGA/PEI
NPs were treated with 0.5 mL of 1 M NaOH and stirred
overnight. The sample (0.5 mL) was diluted with 0.5 mL
of 1 M acetic acid. The resulting solution (0.5 mL) was
added to 1 mL of acetate buffer 0.1 M at pH 4.5 and
complexed with 0.25 mL of a copper (II) sulphate water
solution 0.1 % w/v. The absorbance value of each solu-
tion was recorded at 281 nm (UV 1800, Shimadzu). A
calibration curve was constructed in the same condition
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in the PEI concentration range 15–380 μg/mL. Possible
interference of PLGA on PEI quantitative analysis was
assessed by treating and analyzing a similar amount of
unloaded PLGA NPs in the same conditions.
OVA entrapment efficiency
OVA loading inside NPs was assessed by dissolving 1 mg
of NPs in 500 μL of methylene chloride under stirring for
15 min. Thereafter, 500 μL of water were added and after
stirring for further 15 min, the sample was centrifuged at
2000 x g for 5 min. The supernatant (0.1 mL) was col-
lected and added to 0.9 mL of Bradford reagent. After in-
cubation for 15 min, the absorbance of the solutions was
measured at 595 nm on an UV spectrophotometer (UV
1800, Shimadzu) and compared to a calibration curve gen-
erated in the OVA concentration range 20–1000 μg/mL.
To verify a possible interference of copolymers on OVA
quantitative analysis, an amount of unloaded NPs was
treated and analyzed in the same conditions.
NP stability in cell culture media
The stability of NPs under physiologically relevant condi-
tions was evaluated by placing a known amount of NPs in
DMEM (Dulbecco’s Modified Eagle Medium, Life Tech-
nologies) and RPMI 1640 (Life Technologies) cell culture
media supplemented with FBS 10 % (NP concentration
was 1.5 mg/mL) at 37 °C. Size measurements of the sam-
ples were taken by PCS after 24, 48 and 72 h of incubation.
Nanoparticle uptake
Hepa 1–6 or PBMCs were seeded into each well of a 24-
well culture plate in a maximum volume of 1 mL/well
for induction. PLGA NPs labeled with rhodamine B were
added to the culture medium 24 h later. The final NPs
concentration was adjusted to 20, 50 and 100 μg/mL.
Following different incubation times, the cells were
washed with 1X PBS and further treated for FACS and
CLSM analysis.
FACS analysis
Hepa 1–6 cells were washed twice with 1X PBS and studied
with a FACScalibur flow cytometer (BD FACSCanto II). In
parallel, NP-loaded PBMCs were stained with PerCP-
Cy5.5-anti-human CD14 antibody for 30 min at 4 °C before
analysis.
CLSM analysis
Confocal laser scanning microscopy (CLSM) was applied
to image the Hepa 1–6 and PBMCs after incubation
with NPs. Cells (2x104/sample) were seeded on sterile
glass coverslips and cultured in suitable growth medium.
24 h later, fluorescently labeled NPs were added to the
culture medium with a final concentration of 50 μg/mL.
Following different incubation times, the culture
medium was removed and the cells were rinsed with 1X
PBS. Cover slips were mounted using 20 % (w/v) mowiol
(Sigma-Aldrich). Cells were visualized with a 510 META-
LSM confocal microscopy (Carl Zeiss) and z-series with
0.1 μm intervals were collected. Alternatively, after nu-
clear staining with 4-6-diamidino-2-phenylindole dye
(DAPI), cells were visualized by a fluorescence inverted
microscope connected to a video-camera (Carl Zeiss).
TEM analysis
50 μl of each NP dispersion was applied to a carbon-
coated copper/rhodium grid (400 mesh) (TAAB Labora-
tories Equipment Ltd, Aldermaston, Berks, ENGLAND).
The coated grid was floated for 2 min on the drop,
rinsed with 200 μl of double distilled water and negative
stained by 200 μl of 2 % w/v uranyl acetate solution
(TAAB Laboratories Equipment Ltd). After draining off
the excess of staining solution, the specimen was trans-
ferred to the electron microscope for examination, using
a TEM-Philips Morgagni 282D transmission electron
microscope, operating at 60 kV. Cells incubated with
NPs at 15 min, 30 min and 24 h were processed accord-
ing to embedding standard procedures, i.e., fixation in
2.5 % glutaraldehyde in 1X PBS for 2 h, post-fixation at
4 °C in 1 % osmium tetroxide in the same buffer for 1 h,
bulk staining overnight in 0,5 % aqueous uranyl acetate,
dehydration in graded ethanol dilutions, and embedding
in TAAB Spurr resin (TAAB Laboratories Equipment
Ltd, Aldermaston, Berks, ENGLAND). Diamond thin
sections were stained with lead citrate before TEM ob-
servations at 80 KV accelerating voltage. All the electron
micrographs were photographed on Kodak electron
microscope film 4489 (Kodak Company, New York,
USA).
Human PBMC isolation and DC generation
Fresh human PBMCs were isolated, from EDTA-treated
blood collected from healthy donors, by Ficoll-Hypaque
density gradient centrifugation and plated in 6-well plates
at a concentration of approximately 1 × 106cells/well in a
maximum volume of 2 mL/well.
Monocyte-derived dendritic cells (MDDCs) were gener-
ated as described previously, with minor modifications
[17]. Briefly, isolated PBMCs were allowed to adhere to
plastic in 6-well plates for 2 h. Adherent monocytes were
washed with RPMI 1640 medium and were then cultured
for 6 days in DC culture medium supplemented with 50
ng of recombinant granulocyte-macrophage colony-
stimulating factor (rGM-CSF; R&D Systems, Minneapolis,
Minn.) per mL and 1000 U of recombinant interleukin-4
(rIL-4; R&D Systems, Minneapolis, Minn.) per mL. Imma-
ture DCs (imDCs) were ready for NP treatment.
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Isolation of naïve CD4+ T cells
Naïve CD4+ T cells were isolated from PBMCs by nega-
tive selection with a mixture of mAbs from StemCell
Technologies (Vancouver, British Columbia, Canada),
according to the manufacturer’s instructions. Anti-
human HLA-DR tetrameric mAb (StemCell Technolo-
gies) was also included to increase purity of naïve CD4+
T cells.
Antigen-specific stimulation of autologous naïve CD4+ T
cells ex vivo
Human imDC were pulsed O/N with 1.55 and 7.75 μg
OVA, either soluble or encapsulated in NPs. Cell viabil-
ity was assessed by MTT assay according to the manu-
facturer’s instructions (Sigma). OVA-treated imDCs
(OVA-imDCs) were used directly or stimulated for add-
itional 48 h with LPS (200 ng/mL) to induce DC matur-
ation (OVA-mDCs). OVA-imDCs and OVA-mDCs were
co-cultured for 7 days with autologous naïve CD4+ T
cells labeled with carboxyfluorescein succinimidyl ester
(CellTrace™ CFSE Cell Proliferation Kit; Life Technolo-
gies), according to the manufacturer’s instructions.
Briefly, 5x104 DCs/per well were used for priming au-
tologous naïve CD4+ T cells (2x105 cells/per well) in 200
μl of total culture volume in 96-well plates. The co-
cultures were incubated in a humidified incubator in the
presence of 5 % CO2 at 37 °C for 7 days. T cell prolifera-
tion and differentiation was estimated by flow cytometry
by cell count using antibodies directed against CD4,
CD62L, CD45RO and CD45RA, and CFSE dilution.
After 7 days, supernatants from the assay wells were re-
moved and IFN-γ as well as IL-10 were measured with
the Platinum ELISA kit (eBioscience), according to the
manufacturer’s instructions.
Statistical analyses
Data were analyzed by descriptive statistics, calculating
the mean and standard deviation for continuous variables.
Additional file
Additional file 1: Table S1. Composition and properties of fluorescent
unloaded NPs. SD were calculated on three different batches. (DOCX 17 kb)
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